Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 258

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Molecular Imaging and Biological Evaluation of HuMV833 Anti-VEGF Antibody: Implications for Trial Design of Antiangiogenic Antibodies

Open access
Jayson, G. C., Zweit, J., Jackson, A., Mulatero, C., Julyan, P., Ranson, M., Broughton, L., Wagstaff, J., Hakannson, L., Groenewegen, G., Bailey, J., Smith, N., Hastings, D., Lawrance, J., Haroon, H., Ward, T., McGown, A. T., Tang, M., Levitt, D., Marreaud, S., Lehmann, F. F., Herold, M., Zwierzina, H.·2002·JNCI Journal of the National Cancer Institute

Abstract

BACKGROUND: Vascular endothelial growth factor (VEGF) is a potent angiogenic cytokine, and various inhibitory agents, including specific antibodies, have been developed to block VEGF-stimulated angiogenesis. We developed HuMV833, a humanized version of a mouse monoclonal anti-VEGF antibody (MV833) that has antitumor activity against a number of human tumor xenografts, and investigated the distribution and biologic effects of HuMV833 in patients in a phase I trial. METHODS: Twenty patients with progressive solid tumors were treated with various doses of HuMV833 (0.3, 1, 3, or 10 mg/kg). Positron emission tomography with (124)I-HuMV833 was used to measure the antibody distribution in and clearance from tissues. Magnetic resonance imaging was used to measure the vascular permeability surface area product with a first-pass pharmacokinetic model (k(fp)) to determine tumor vascular permeability. RESULTS: The antibody was generally well tolerated, although the incremental dose, phase I study design, and pharmacodynamic endpoints could not identify the optimum biologically active dose. Antibody distribution and clearance were markedly heterogeneous between and within patients and between and within individual tumors. HuMV833 distribution to normal tissues also varied among patients, but the antibody was cleared from these tissues in a homogeneous fashion. Permeability was strongly heterogeneous between and within patients and between and within individual tumors. All tumors showed a reduction in k(fp) 48 hours after the first treatment (median = 44%; range = 4%-91%). CONCLUSIONS: Because of the heterogeneity in tumor biology with respect to antibody uptake and clearance, we suggest that either intrapatient dose escalation approaches or larger, more precisely defined patient cohorts would be preferable to conventional strategies in the design of phase I studies with antiangiogenic compounds like HuMV833.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/jnci/94.19.1484

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 258

Metadata

Authors
Jayson, G. C., Zweit, J., Jackson, A., Mulatero, C., Julyan, P., Ranson, M., Broughton, L., Wagstaff, J., Hakannson, L., Groenewegen, G., Bailey, J., Smith, N., Hastings, D., Lawrance, J., Haroon, H., Ward, T., McGown, A. T., Tang, M., Levitt, D., Marreaud, S., Lehmann, F. F., Herold, M., & Zwierzina, H.
Venue
JNCI Journal of the National Cancer Institute
Published
2002-10-02
Volume
94
Issue
19
Pages
1484-1493
ISSN
  • 0027-8874 (ISSN-L)
  • 1460-2105
OpenAlex
W2141114204
Cited by
258
References
1
FWCI
5.94
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Molecular Imaging and Biological Evaluation of HuMV833 Anti-VEGF Antibody: Implications for Trial Design of Antiangiogenic Antibodies. https://app.cochat.ai/papers/10.1093/jnci/94.19.1484
The paper
Jayson, G. C., Zweit, J., Jackson, A., Mulatero, C., Julyan, P., Ranson, M., Broughton, L., Wagstaff, J., Hakannson, L., Groenewegen, G., Bailey, J., Smith, N., Hastings, D., Lawrance, J., Haroon, H., Ward, T., McGown, A. T., Tang, M., Levitt, D., . . . Zwierzina, H. (2002). Molecular Imaging and Biological Evaluation of HuMV833 Anti-VEGF Antibody: Implications for Trial Design of Antiangiogenic Antibodies. JNCI Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/94.19.1484

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.